Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06073873Recruiting
Safety study of ozanimod for ulcerative colitis in Korea
This study is checking the safety of ozanimod, a daily pill, for people with moderate to severe active ulcerative colitis. It looks at how well patients tolerate the medicine in real-world use in Korea.
SeoulAges 19 years+ - NCT07765888RecruitingPhase 3
Tilrekimig for moderate-to-severe eczema
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
Northridge, CaliforniaAges 12 years+ - NCT07759245RecruitingPhase 2
Brenipatide for moderate-to-severe COPD
This trial tests a new medicine called Brenipatide to see if it can help people with moderate-to-severe COPD who still have symptoms despite using standard inhalers. The study will compare the effects of Brenipatide against a placebo to understand if it is safe and effective.
Birmingham, AlabamaAges 40–75 - NCT07759752Recruiting
Two minimally invasive treatments for enlarged prostate symptoms
This trial compares two minimally invasive procedures to relieve urinary symptoms caused by an enlarged prostate. Both treatments aim to open the urethra without major surgery, and the goal is to improve your urine flow and reduce bothersome symptoms.
Hong KongAges 50–80 - NCT07753603RecruitingPhase 3
Linsitinib for active moderate to severe thyroid eye disease
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Las Vegas, NevadaAges 18 years+ - NCT07743671RecruitingPhase 3
Engasertib for frequent nosebleeds from HHT
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
Chicago, IllinoisAges 18 years+ - NCT07746583Recruiting
Switching from ustekinumab to guselkumab for psoriasis
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
BudapestAges 18 years+ - NCT07748728Enrolling by invitationPhase 2
Study of TLL-018 for rheumatoid arthritis after standard treatments fail
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07746817RecruitingPhase 1
Study of a new drug for eczema
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
Melbourne, VictoriaAges 18–55 - NCT07748091Recruiting
Brain wave and inflammation markers in shock therapy for depression
This study looks at brain wave patterns and markers of inflammation in people with depression that hasn't improved with other treatments and who are receiving electroconvulsive therapy (ECT, also known as shock therapy). The goal is to understand how these markers might relate to how well ECT works.
Istanbul, BakırköyAges 18–60 - NCT07734441RecruitingEarly Phase 1
Itraconazole vs Ketoconazole for Scalp Seborrheic Dermatitis
This study compares two treatments—itraconazole pills and ketoconazole shampoo—for moderate to severe dandruff on the scalp. It aims to find which works better for teens aged 14–17.
Chak Four Hundred Fifty-four, Punjab ProvinceAges 18–65 - NCT07740694Recruiting
ECT study for older adults with depression
This study looks at how ECT affects brain activity and inflammation in older adults with depression. It may help researchers understand why ECT works and improve treatment.
Istanbul, BakırköyAges 55 years+ - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT07724366RecruitingPhase 3
Study of TQH3906 for moderate to severe plaque psoriasis
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07725939RecruitingPhase 2
Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Miami, FloridaAges 40–80 - NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07721441Enrolling by invitation
Predicting Gut Healing in Ulcerative Colitis with a Stool Test
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07723144Recruiting
Identifying sleep apnea biomarkers
This study compares blood samples from people with moderate-to-severe sleep apnea and those without sleep apnea to find markers that could help diagnose or treat the condition. Half of those with sleep apnea will start CPAP therapy right away, while others wait before starting.
Bialystok, Podlaskie VoivodeshipAges 18–65 - NCT07709754Recruiting
Lung stimulation for hard-to-control asthma
This trial tests a device that stimulates the lung to help people whose asthma is not controlled by standard treatments. It may offer a new option for those who still have symptoms despite using inhalers or biologic medicines.
Denver, ColoradoAges 18–75 - NCT07693738RecruitingPhase 1
SSGJ-716 for healthy adults and people with atopic dermatitis
This trial tests a new medicine, SSGJ-716, in healthy adults and in people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and how the body reacts to it.
ShanghaiAges 18–45 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07686081RecruitingPhase 3
Testing ponesimod for moderate to severe ulcerative colitis
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT07668518RecruitingPhase 1/Phase 2
Study of KIT2014 for moderate to severe COPD
This trial tests a new medicine called KIT2014 in people with moderate to severe COPD. It aims to see if the drug is safe, tolerable, and helps improve breathing and COPD symptoms.
Charlestown, New South WalesAges 40–80 - NCT07663526RecruitingPhase 4
Tabellvi for moderate to severe Crohn's disease in adults
This trial tests Tabellvi (adalimumab) for adults with moderate to severe Crohn's disease who haven't responded well to steroids or other treatments. It aims to see if this medication can help control symptoms and improve quality of life.
Fuyang, AnhuiAges 18–70
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.